FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson

CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARRO^TM (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO was approved by the U.S. Food and Drug Administration (FDA) on November 22,2021. This therapy is a mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

“Patients with advanced malignant PEComa have few treatment options and face a poor prognosis,” said Ela Lourido, vice president, Biopharma Services, Biologics. “We are honored to be selected by Aadi Bioscience to bring a treatment option to these patients.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial, and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506), or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.